HER2+ Breast Cancer Treatment | PERJETA® (pertuzumab)
WEBuse prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
How does PERJETA® (pertuzumab) treat HER2+ Breast Cancer?
WEBPERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Adjuvant Treatment for Breast Cancer | PERJETA® (pertuzumab)
WEBEarly breast cancer treatment after surgery. People with early breast cancer usually get treatment after surgery, even if the surgery was successful. This is called adjuvant treatment. After early breast cancer surgery, PERJETA is approved in combination with Herceptin ® (trastuzumab) and chemotherapy for people with HER2+ early breast …
Early breast cancer treatment before surgery - perjeta
WEBFor some people with early breast cancer, it may be beneficial to start treatment before having surgery. This is called neoadjuvant treatment. Prior to surgery, PERJETA is approved for use in combination with Herceptin ® (trastuzumab) and chemotherapy in people with HER2+, locally advanced, inflammatory, or early stage breast cancer (tumor ...
PERJETA for HER2+ metastatic breast cancer
WEBPERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Treatment for HER2+ early breast cancer - perjeta
WEBPERJETA is a targeted cancer treatment that can be started before surgery (neoadjuvant) and may be started or continued after surgery (adjuvant). It is given in combination with a medication called Herceptin ® (trastuzumab) and chemotherapy.
PERJETA® (pertuzumab) for HER2+ Metastatic Breast Cancer
WEBPERJETA and Herceptin-based therapy may be an appropriate option for people with HER2+ metastatic breast cancer that: Has spread to other parts of the body (metastatic), and. Has NOT been treated with traditional chemotherapy or HER2-targeted treatments before for metastatic breast cancer.
Early Breast Cancer IV Infusion | PERJETA® (pertuzumab)
WEBPERJETA is given every 3 weeks as an IV infusion. PERJETA is given as an intravenous (IV) infusion, which means that medication is administered directly into the bloodstream through a vein. PERJETA and Herceptin ® (trastuzumab) …
Downloads and Resources | PERJETA® (pertuzumab)
WEBPERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Metastatic Breast Cancer IV Infusion | PERJETA® (pertuzumab)
WEBPERJETA is given as an intravenous (IV) infusion, which means that medication is administered directly and slowly into the bloodstream through a vein. When you begin treatment, your doctor will start PERJETA, Herceptin ® (trastuzumab), and docetaxel at the same time, and may adjust the medicines in your treatment plan over time.